Avoro Ventures
Signal active
Investment Firm
Overview
Avoro Ventures is an investment firm that manages biopharma venture funds.
Highlights
Founded
Invalid date
Industry
Financial Services
Employees
0
Investment
4
Lead Investment
1
Exits
1
Stages
Early Stage Venture
Investor Type
Venture Capital
Location
New York, New York, United States, North America
Contact Information
Social
N/A
Profile Resume
Avoro Ventures, established in Unknown year and headquartered in New York, New York, United States, North America., specializes in Early Stage Venture investments across Biotechnology, Life Science, Pharmaceutical, Finance, Business Development, Application Performance Management, Financial Services, Venture Capital, FinTech, Health Care. The organization boasts a portfolio of 4 investments, with an average round size of $118.7M and 1 successful exits. Their recent investments include Hemab, Invus, Novo Holdings, Access Biotechnology, RA Capital Management. The highest investment round they participated in was $61.0B. Among their most notable exits are Hemab and Invus. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Employees
N/A
Investment portfolio
Avoro Ventures has made 4 investments. Their most recent investment was on Feb 21, 2023, when Hemab raised $135.0M.
Avoro Ventures has made 1 diversity investments. Their most recent diversity investment was on Mar 31, 2021, when Scribe Therapeutics raised $100.0M.
investments
4
Diversity investments
1
Lead investments
1
Number of exits
1
Investments
4
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Mar 31, 2021 | Scribe Therapeutics | Biotechnology | 100.0M |
| Aug 26, 2021 | Aadi Bioscience | Biotechnology | 155.0M |
| Sep 14, 2021 | Vanqua Bio | Biotechnology | 85.0M |
| Feb 21, 2023 | Hemab | Biotechnology | 135.0M |
Exits
1
Funding Timeline
Funding rounds
4
Investors
0
Funds
1
Funding Rounds
4
Avoro Ventures has raised 4 rounds. Their latest funding was raised on Feb 21, 2023 from a Series B - Hemab round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Mar 31, 2021 | Series B - Scribe Therapeutics | - | 100.0M | - |
| Aug 26, 2021 | Post-IPO Equity - Aadi Bioscience | - | 155.0M | - |
| Sep 14, 2021 | Series B - Vanqua Bio | - | 85.0M | - |
| Feb 21, 2023 | Series B - Hemab | - | 135.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.